Pharming Group Files Its Annual Report and 20-F for 2024

Author: Kelly Martin Updated: 04-03-2025 01:18 AM

Pharming Group's Annual Report and Form 20-F Submission

Pharming Group N.V. (Euronext Amsterdam: PHARM / Nasdaq: PHAR), a leading biopharmaceutical company, has recently completed the filing of its 2024 Annual Report. This detailed report covers the fiscal year ending on December 31, 2024, and is a testament to the company’s ongoing efforts in advancing treatments for patients facing serious health challenges.

Accessing the Annual Report

The 2024 Annual Report is readily accessible via the company’s official website, particularly through the Investors section under Financial documents. Interested parties can easily navigate to Pharming.com to review this comprehensive document. This filing exemplifies Pharming's commitment to transparency and regulatory compliance.

Filing with the U.S. Securities and Exchange Commission

In addition to its primary Annual Report, Pharming has also submitted its Form 20-F to the U.S. Securities and Exchange Commission (SEC). This form is essential for foreign companies listed in the United States, enabling them to provide important financial information to investors. After the filing, the 2024 Form 20-F will be available on both the Pharming website and the SEC's platform, ensuring that stakeholders have access to crucial updates.

About Pharming Group N.V.

Pharming Group N.V. is dedicated to the development and commercialization of innovative therapies for patients suffering from rare and severe diseases. With its headquarters in Leiden, the Netherlands, Pharming operates on a global scale, addressing the critical healthcare needs of patients across over 30 countries including North America, Europe, and Asia-Pacific.

Vision and Commitment

The company’s portfolio showcases a blend of both small molecules and biologics, underscoring its innovative approach to healthcare. Pharming’s focus lies in the relentless pursuit of breakthroughs that can significantly enhance the quality of life for patients dealing with debilitating health conditions.

Contact Information for Further Inquiries

Those seeking more information about Pharming's initiatives, products, or financial reports can reach out to the company’s Investor Relations. Here are the details for contacting Pharming Group:

Pharming Group, Leiden
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

FTI Consulting, London, UK
Simon Conway/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Frequently Asked Questions

What is the primary purpose of the Annual Report filed by Pharming?

The Annual Report provides insights into the company's performance, financial health, and strategic direction for stakeholders and investors.

Where can I access Pharming's Annual Report?

The Annual Report can be found under the Investors section of the Pharming website, making it easily accessible for everyone interested.

What is included in the Form 20-F filed with the SEC?

The Form 20-F includes key financial statements and disclosures required for listed companies, ensuring transparency and compliance with U.S. regulations.

Who is Pharming Group's target patient population?

Pharming targets patients with rare, debilitating diseases, focusing on those who face significant health challenges without adequate treatment options.

How can investors communicate with Pharming Group?

Investors can directly reach out to Pharming’s VP of Investor Relations, Michael Levitan, via the provided contact details for any inquiries.

About The Author

Hello Kelly Martin here, a financial and publicly traded company specialist committed to writing with clarity and sage advice. Having a wealth of experience and a thorough grasp of corporate dynamics and the financial environment, my main goal in writing blog posts and articles is to provide insightful analysis together with useful guidance. My objective is to arm readers with the information they need to comprehend the complexities of publicly traded companies and make wise financial decisions.

Writing for several financial blogs has let me interact with a wide range of readers, from novice investors to seasoned pros looking for fresh perspectives. My goal is to make corporate analysis and finance understandable and interesting so you may confidently negotiate the intricacies of the financial world. I appreciate you traveling with me toward success and financial literacy.

Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.